Despite the availability of numerous approved antihypertensive drugs, difficult-to-control and resistant hypertension are persistent and are major risk factors for cardiovascular disease. Emerging and investigational treatments that are currently being explored to target hypertension include firibrastat, empagliflozin and interventional procedures, including improved approaches to renal artery denervation and a novel baroreceptor device implantation. Firibrastat is an investigational drug that specifically and selectively inhibits aminopeptidase A leading to decreased formation of angiotensin III in the brain, resulting in decreased blood pressure. Sodium-glucose cotransporter-2 inhibitors, such as empagliflozin used to treat type 2 diabetes, may be beneficial as antihypertensive agents. Empagliflozin in a recent study demonstrated significant reductions in high blood pressure in an African American population. Advances in renal artery denervation and an investigational baroreceptor device implantation also show promise as potential interventions in patients with difficult-to-control and resistant hypertension.

中文翻译：

---

NEW-HOPE研究和针对难以控制和抗药性高血压的新兴疗法。

尽管可获得许多批准的降压药，但难以控制和抵抗的高血压持续存在，并且是心血管疾病的主要危险因素。目前正在研究针对高血压的新兴和研究性治疗方法，包括firibrastat，依帕格列净和介入治疗，包括改进的肾动脉去神经支配方法和新型压力感受器植入。Firibrastat是一种研究药物，可特异性和选择性地抑制氨基肽酶A，从而导致大脑中血管紧张素III的形成减少，从而导致血压降低。钠-葡萄糖共转运蛋白2抑制剂（例如用于治疗2型糖尿病的依帕列净）可能是有益的抗高血压药。Empagliflozin在最近的一项研究中证明非裔美国人的血压显着降低。肾动脉去神经支配和研究性压力感受器装置的植入也显示出有望作为难以控制和抵抗性高血压患者的潜在干预手段。